El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, Barreto FC. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev. 2016;7:CD006663. doi: 742. Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, Kantola I, Linhart A, Mignani R, Namdar M, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry dis- ease: a systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19:100454. doi: 10.1016/j.ymgmr.2019.100454 743. Rolfs A, B ttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, Walter U, Mix E, L hr M, Harzer K, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005;366:1794 744. Wozniak MA, Kittner SJ, Tuhrim S, Cole JW, Stern B, Dobbins M, Grace ME, Nazarenko I, Dobrovolny R, McDade E, et al. Frequency of unrec- ognized Fabry disease among young European-American and African- American men with first ischemic stroke. Stroke. 2010;41:78 81. doi: 745. Bersano A, Kraemer M, Burlina A, Mancuso M, Finsterer J, Sacco S, Salvarani C, Caputi L, Chabriat H, Oberstein SL, et al. Heritable and non-heritable uncommon causes of stroke [published on- line April 21, 2020]. J Neurol. doi: 10.1007/s00415-020-09836-x. 746. Koga Y, Povalko N, Inoue E, Nakamura H, Ishii A, Suzuki Y, Yoneda M, Kanda F, Kubota M, Okada H, et al. Therapeutic regimen of L-arginine for MELAS: 9-year, prospective, multicenter, clinical research. J Neurol. 747. El-Hattab AW, Almannai M, Scaglia F. Arginine and citrulline for the treat- ment of MELAS syndrome. J Inborn Errors Metab Screen. 2017;5:10.1177 748. Haussen DC, Grossberg JA, Bouslama M, Pradilla G, Belagaje S, Bianchi N, Allen JW, Frankel M, Nogueira RG. Carotid web (intimal fibromuscular dysplasia) has high stroke recurrence risk and is amenable to stenting. 749. 